Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 4, 2007, Pages

  Johnson, Kathryn M S ^a,b   Edgerton, Dale S ^a   Rodewald, Tiffany ^a   Scott, Melanie ^a   Farmer, Ben ^a   Neal, Doss ^a   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Dog; Glucagon like peptide 1; Hepatic portal vein; Liver

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; PANCREAS HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOG; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HEPATIC ARTERY; HORMONE BLOOD LEVEL; HORMONE RELEASE; INSULIN BLOOD LEVEL; MALE; NONHUMAN; OUTCOME ASSESSMENT; PORTAL VEIN; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; DOGS; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; INFUSIONS, INTRAVENOUS; INSULIN; LIVER; MALE; PANCREATIC HORMONES; PORTAL VEIN; REGIONAL BLOOD FLOW;

EID: 35148832136     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00275.2007     Document Type: Article

References (26)

1. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279: R1449-R1454, 2000.
2. Burcelin R, Da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50: 1720-1728, 2001.
3. Burcelin R, Dolci W, Thorens B. Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization. Diabetes 49: 1635-1642, 2000.
4. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48: 1198-1214, 1999.
5. Dardevet D, Moore MC, DiCostanzo CA, Farmer B, Neal DW, Snead W, Lautz M, Cherrington AD. Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am J Physiol Gastrointest Liver Physiol 289: G806-G814, 2005.
6. Drucker DJ. The biology of incretin hormones. Cell Metab 3: 153-165, 2006.
7. Hendrick GK, Frizzell RT, Williams PE, Cherrington AD. Effect of hyperglucagonemia on hepatic glycogenolysis and gluconeogenesis after a prolonged fast. Am J Physiol Endocrinol Metab 258: E841-E849, 1990.
8. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48: 612-615, 2005.
9. Ionut V, Hucking K, Liberty IF, Bergman RN. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 48: 967-975, 2005.
10. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596, 1995.
11. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88: 2719-2725, 2003.
12. Moore MC, Cardin S, Edgerton DS, Farmer B, Neal DW, Lautz M, Cherrington AD. Unlike mice, dogs exhibit effective glucoregulation during low-dose portal and peripheral glucose infusion. Am J Physiol Endocrinol Metab 286: E226-E233, 2004.
13. Myers SR, McGuinness OP, Neal DW, Cherrington AD. Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration. J Clin Invest 87: 930-939, 1991.
14. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol Endocrinol Metab 271: E808-E813, 1996.
15. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76: 912-917, 1993.
16. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307, 1993.
17. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997.
18. Niijima A. The effect of D-glucose on the firing rate of glucose-sensitive vagal afferents in the liver in comparison with the effect of 2-deoxy-D-glucose. J Auton Nerv Syst 10: 255-260, 1984.
19. Nishizawa M, Moore MC, Shiota M, Gustavson SM, Snead WL, Neal DW, Cherrington AD. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. Am J Physiol Endocrinol Metab 284: E1027-E1036, 2003.
20. Pagliassotti MJ, Holste LC, Moore MC, Neal DW, Cherrington AD. Comparison of the time courses of insulin and the portal signal on hepatic glucose and glycogen metabolism in the conscious dog. J Clin Invest 97: 81-91, 1996.
21. Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285: E701-E707, 2003.
22. Sahin M, Tanaci N, Yucel M, Tutuncu NB, Guvener N. The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients. Clin Endocrinol (Oxf). In press.
23. Schirra J, Goke B. The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul Pept 128: 109-115, 2005.
24. Sindelar DK, Balcom JH, Chu CA, Neal DW, Cherrington AD. A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog. Diabetes 45: 1594-1604, 1996.
25. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, D'Alessio DA. GLP-1 receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology. In press.
26. Vella A, Rizza RA. Extrapancreatic effects of GIP and GLP-1. Horm Metab Res 36: 830-836, 2004.